STAT3 and neoplasm: In dendritic cells, JAK1/STAT3 signaling represses IL-12 production by inhibiting the recruitment of cyclin-dependent kinase 9/positive transcription elongation factor b (CDK9/P-TEFb) to the IL-12p35 promoter, thereby impairing anti-tumor immune responses [121].